Tag - ISEE

Markets

HCW starts IVERIC Bio at buy; PT $20

H.C. Wainwright launched coverage of IVERIC Bio (NASDAQ:ISEE) with a “buy” rating and price target of $20. The stock closed at $9.07 on Aug. 18. Analyst Matthew Caufield writes that IVERIC’s retinal platform...

August 19, 2021

Developments

IVERIC bio Zimura meets primary endpoint in Phase 2b dry AMD trial

Based on initial topline data, IVERIC bio’s (NASDAQ:ISEE) Zimura met its prespecified primary endpoint in a Phase 2b dry age-related macular degeneration (AMD) clinical trial. IVERIC’s Phase 2b trial assessed Zumira, a...

October 28, 2019

Tag - ISEE

HCW starts IVERIC Bio at buy; PT $20

IVERIC bio Zimura meets primary endpoint in Phase 2b dry AMD trial

General

More